Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Peregrine plunges on bad bavituximab data

21:20 EDT 27 Jun 2013 | SCRIP

Tustin, California-based Peregrine buried its latest bad clinical trial news in the middle of a press release regarding the Phase III trial design for bavituximab plus docetaxel in the second-line treatment of non-small cell lung cancer (NSCLC). The....

Original Article: Peregrine plunges on bad bavituximab data

NEXT ARTICLE

More From BioPortfolio on "Peregrine plunges on bad bavituximab data"

Search BioPortfolio:

Relevant Topic

Gilotrif (afatinib) · Latest News · Clinical Trials · Research · Drugs · Reports · Corporate
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...

Advertisement
Advertisement

Searches Linking to this Story